About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The group of Clinical Neuroimmunology - Centre d'Esclerosi Múltiple de Catalunya (Cemcat) at the Vall d'Hebron Institut de Recerca (VHIR) is a multidisciplinary group dedicated to clinical assistance, physical and cognitive rehabilitation, and clinical and basic research on multiple sclerosis (MS). Cemcat is a national but also an international reference center in the clinical assistance of MS patients. The research performed in the group is divided and further combined in clinical and basic research. In addition, basic research has a marked translational character since the ultimate goal of the group is to improve the quality of life of patients suffering from MS, through in-depth knowledge of the pathogenic mechanisms of the disease and the development of new and more effective therapeutic approaches.
IP: Carmen Tur Gomez Collaborators: Carlos Domínguez Pérez, Miriam Izquierdo Sans Funding agency: Instituto de Salud Carlos III Funding: 242500 Reference: CP23/00117 Duration: 01/01/2024 - 31/12/2028
IP: Manuel Comabella Lopez Collaborators: - Funding agency: EUROPEAN COMMISSION Funding: 248720 Reference: BEHIND-MS_HE-HLTH2023 Duration: 01/12/2023 - 30/11/2028
IP: Manuel Comabella Lopez Collaborators: - Funding agency: Ministerio de Ciencia e Innovación-MICINN Funding: 0.01 Reference: RED2022-134511-T Duration: 01/06/2023 - 31/05/2025
IP: Manuel Comabella Lopez Collaborators: Laia Perez Lasarte, Elisa Marín Ordovás, Miriam Izquierdo Sans Funding agency: Fundació Institut de Recerca HUVH Funding: 69188.74 Reference: VPHD/ELISA_M Duration: 01/04/2023 - 31/03/2026
A Vall d’Hebron study, carried out at Cemcat, shows that the risk of inflammatory activity increases after discontinuing treatment, but is considerably reduced in people over 60 years of age.
The project will analyse the functional activation of the NLRP3 inflammasome to advance the early identification of patients at risk of insufficient response to S1P receptor-modulating therapies.
Anti-Müllerian hormone had been proposed as a potential biomarker for predicting disease prognosis in women, but this study shows that the observed association is explained by patients’ chronological age.
Simoa HD1 equipment
2026 SIMOA HD1 Rates
PDF 0.47 MB
SIMOA HD1 Rates - historical
PDF 0.15 MB
